ArriVent Q2 net loss widens to $49.89 million; R&D expenses rise to $42.34 million
AVBP•Pipeline timing
- Topline Phase 3 FURVENT data for firmonertinib in first-line EGFR exon 20 insertion NSCLC is expected in 2H 2026.
- First ARR-002 patient dosing is expected in Q3 2026.
Second-quarter results and expenses
- ArriVent posted a Q2 net loss of $49.89 million, widening from $31.4 million a year earlier.
- R&D expense climbed to $42.34 million from $27.72 million, while G&A rose to $10.35 million from $5.9 million.
- Operating loss widened to $52.69 million from $33.62 million; interest and investment income increased to $2.8 million from $2.22 million.
- Cash and investments totaled $373.1 million at June 30, expected to fund operations into 2028.
